Synapse - Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial

Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial Meeting Abstract

Authors:	Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; Wills, A.; Korde, N.; Lendvai, N.; Lesokhin, A. M.; Hassoun, H.; Hultcrantz, M.; Landau, H. J.; Shah, G. L.; Scordo, M.; Chung, D. J.; Lahoud, O. B.; Khattar, P.; Fernandez de Larrea, C.; Gao, Q.; Jungbluth, A.; Park, J. H.; Curran, K. J.; Sauter, C. S.; Palomba, M. L.; Senechal, B.; Wang, X.; Dogan, A.; Giralt, S.; Riviere, I.; Landgren, O.; Brentjens, R. J.; Smith, E. L.
Abstract Title:	Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
Meeting Title:	60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	132
Issue:	Suppl. 1
Meeting Dates:	2018 Dec 1-4
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2018-11-29
Language:	English
ACCESSION:	WOS:000454837602335
PROVIDER:	wos
DOI:	10.1182/blood-2018-99-119717
Notes:	Meeting Abstract: 959 -- Source: Wos